# Jonathan R. Strosberg

Source: https://onco.cc/people/jonathan-strosberg/  
OnCo record `jonathan-strosberg` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led NETTER-1, the trial that made lutetium dotatate the first approved radioligand therapy for neuroendocrine tumours.

## Summary

Jonathan Strosberg was principal investigator of NETTER-1, which showed 177Lu-DOTATATE reduces the risk of progression by 79% in midgut neuroendocrine tumours and led to Lutathera's approval, the first radioligand therapy approved for a solid tumour and the template for PSMA-targeted therapy. He co-leads the NETTER-2 and COMPETE programmes and chairs the North American Neuroendocrine Tumor Society guidelines.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: neuroendocrine; radioligand; trialist
- Role: Section Head, Neuroendocrine Tumor Program, Moffitt Cancer Center
- Specialisms: Neuroendocrine tumours; Peptide receptor radionuclide therapy; Somatostatin analogues; Radioligand trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Strosberg%20J%5BAuthor%5D%20neuroendocrine%20lutetium

## Connected records

- cancers: [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/)
- technologies: [Radioligand therapy (beta emitters)](https://onco.cc/technologies/radioligand-therapy/)
- targets: [Somatostatin receptor 2](https://onco.cc/targets/sstr2/)
- drugs: [Lutetium-177 dotatate](https://onco.cc/drugs/lutathera/)
- institutions: [Moffitt Cancer Center](https://onco.cc/institutions/moffitt/)
- trials: [COMPETE](https://onco.cc/trials/compete/)
- key papers: [NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours](https://onco.cc/key-papers/paper-netter-2-lancet-2024/)

---
JSON: https://onco.cc/api/v1/entities/jonathan-strosberg.json